119 related articles for article (PubMed ID: 8947060)
1. Aerosolized rhDNase in cystic fibrosis: effect on leucocyte proteases in sputum.
Rochat T; Pastore FD; Schlegel-Haueter SE; Filthuth I; Auckenthaler R; Belli D; Suter S
Eur Respir J; 1996 Nov; 9(11):2200-6. PubMed ID: 8947060
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil proteinases and rhDNase therapy in cystic fibrosis.
Vogelmeier C; Döring G
Eur Respir J; 1996 Nov; 9(11):2193-5. PubMed ID: 8947058
[No Abstract] [Full Text] [Related]
3. The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis.
Shah PL; Scott SF; Knight RA; Hodson ME
Eur Respir J; 1996 Mar; 9(3):531-4. PubMed ID: 8730015
[TBL] [Abstract][Full Text] [Related]
4. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients.
Hansen G; Hoffjan S; Mosler K; Schuster A
Lung; 2001; 179(3):185-94. PubMed ID: 11891608
[TBL] [Abstract][Full Text] [Related]
5. Influence of DNA on the activities and inhibition of neutrophil serine proteases in cystic fibrosis sputum.
Dubois AV; Gauthier A; Bréa D; Varaigne F; Diot P; Gauthier F; Attucci S
Am J Respir Cell Mol Biol; 2012 Jul; 47(1):80-6. PubMed ID: 22343221
[TBL] [Abstract][Full Text] [Related]
6. Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis.
Costello CM; O'Connor CM; Finlay GA; Shiels P; FitzGerald MX; Hayes JP
Thorax; 1996 Jun; 51(6):619-23. PubMed ID: 8693445
[TBL] [Abstract][Full Text] [Related]
7. EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis.
Attucci S; Gauthier A; Korkmaz B; Delépine P; Martino MF; Saudubray F; Diot P; Gauthier F
J Pharmacol Exp Ther; 2006 Aug; 318(2):803-9. PubMed ID: 16627747
[TBL] [Abstract][Full Text] [Related]
8. DNase I acutely increases cystic fibrosis sputum elastase activity and its potential to induce lung hemorrhage in mice.
Cantin AM
Am J Respir Crit Care Med; 1998 Feb; 157(2):464-9. PubMed ID: 9476859
[TBL] [Abstract][Full Text] [Related]
9. Cystic fibrosis sputum induces a secretory response from airway gland serous cells that can be prevented by neutrophil protease inhibitors.
Schuster A; Fahy JV; Ueki I; Nadel JA
Eur Respir J; 1995 Jan; 8(1):10-4. PubMed ID: 7744174
[TBL] [Abstract][Full Text] [Related]
10. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.
Shah PL; Scott SF; Knight RA; Marriott C; Ranasinha C; Hodson ME
Thorax; 1996 Feb; 51(2):119-25. PubMed ID: 8711640
[TBL] [Abstract][Full Text] [Related]
11. DNA quantification and fragmentation in sputum after inhalation of recombinant human deoxyribonuclease.
Riethmueller J; Vonthein R; Borth-Bruhns T; Grassmé H; Eyrich M; Schilbach K; Stern M; Gulbins E
Cell Physiol Biochem; 2008; 22(1-4):347-52. PubMed ID: 18769062
[TBL] [Abstract][Full Text] [Related]
12. Poly-L-Lysine compacts DNA, kills bacteria, and improves protease inhibition in cystic fibrosis sputum.
Dubois AV; Midoux P; Gras D; Si-Tahar M; Bréa D; Attucci S; Khelloufi MK; Ramphal R; Diot P; Gauthier F; Hervé V
Am J Respir Crit Care Med; 2013 Sep; 188(6):703-9. PubMed ID: 23947381
[TBL] [Abstract][Full Text] [Related]
13. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum.
Witko-Sarsat V; Halbwachs-Mecarelli L; Schuster A; Nusbaum P; Ueki I; Canteloup S; Lenoir G; Descamps-Latscha B; Nadel JA
Am J Respir Cell Mol Biol; 1999 Apr; 20(4):729-36. PubMed ID: 10101005
[TBL] [Abstract][Full Text] [Related]
14. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
King M; Dasgupta B; Tomkiewicz RP; Brown NE
Am J Respir Crit Care Med; 1997 Jul; 156(1):173-7. PubMed ID: 9230743
[TBL] [Abstract][Full Text] [Related]
15. Impact of PEGylation on the mucolytic activity of recombinant human deoxyribonuclease I in cystic fibrosis sputum.
Guichard MJ; Kinoo D; Aubriot AS; Bauwens N; Gougué J; Vermeulen F; Lebecque P; Leal T; Vanbever R
Clin Sci (Lond); 2018 Jul; 132(13):1439-1452. PubMed ID: 29871879
[TBL] [Abstract][Full Text] [Related]
16. Sputum peroxidase activity correlates with the severity of lung disease in cystic fibrosis.
Regelmann WE; Siefferman CM; Herron JM; Elliott GR; Clawson CC; Gray BH
Pediatr Pulmonol; 1995 Jan; 19(1):1-9. PubMed ID: 7675551
[TBL] [Abstract][Full Text] [Related]
17. Effects of sputum oscillations and rhDNase in vitro: a combined approach to treat cystic fibrosis lung disease.
Dasgupta B; Brown NE; King M
Pediatr Pulmonol; 1998 Oct; 26(4):250-5. PubMed ID: 9811074
[TBL] [Abstract][Full Text] [Related]
18. Fibronectin-cleaving activity in bronchial secretions of patients with cystic fibrosis.
Suter S; Schaad UB; Morgenthaler JJ; Chevallier I; Schnebli HP
J Infect Dis; 1988 Jul; 158(1):89-100. PubMed ID: 3292666
[TBL] [Abstract][Full Text] [Related]
19. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis.
Suri R; Marshall LJ; Wallis C; Metcalfe C; Bush A; Shute JK
Am J Respir Crit Care Med; 2002 Aug; 166(3):352-5. PubMed ID: 12153969
[TBL] [Abstract][Full Text] [Related]
20. DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase.
Brandt T; Breitenstein S; von der Hardt H; Tümmler B
Thorax; 1995 Aug; 50(8):880-2. PubMed ID: 7570441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
